Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery

15 de novembro de 2026 atualizado por: Ain Shams University

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

  1. Pre-operative settings:

    Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).

    Patients will be divided into two groups:

    Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.

    Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.

  2. Intraoperative Settings:

All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.

ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.

Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.

Intra-operative bradycardia (pulse rate <50) will be treated with atropine 0.6 mg.

Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.

Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.

Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.

Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.

Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.

  1. Hemodynamic monitoring:

    Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.

  2. Assessment of post-operative pain & sedation:

By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.

Tipo de estudo

Intervencional

Inscrição (Estimado)

50

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Hala said Hassan, MD
  • Número de telefone: +201147784179

Locais de estudo

    • Abbassia, Egypt
      • Cairo, Abbassia, Egypt, Egito
        • Recrutamento
        • Ain Shams University
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Patients aged from 21-60 years.
  • Patients ASA I or II undergoing elective Robot-Assisted gynecological surgery under general anesthesia.

Exclusion Criteria:

  • Patient refusal.
  • ASA III and ASA IV.
  • A known history of allergy to the drugs used.
  • Patients on chronic steroid therapy.
  • Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Group D (Dexmedetomidine)

Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery.

IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end.

Comparador de Placebo: Group P (Placebo)

Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion).

Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Serum Cortisol Level
Prazo: Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels.

Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Time to First Rescue Analgesia
Prazo: Up to 24 hours postoperatively

The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain

  • 1-3: Mild pain
  • 4-6: Moderate pain
  • 7-10: Severe pain
Up to 24 hours postoperatively
Serum Glucose level
Prazo: Serum glucose: Baseline, just after incision, and 6 hours post-induction.

Blood serum level of glucose to assess metabolic stress.

Serum glucose: Baseline, just after incision, and 6 hours post-induction.
Numerical Pain Distress Scale (NPDS) Score
Prazo: Upon recovery in PACU and throughout the first 24 hours postoperatively.

Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain).

Higher number means high pain intensity.

Upon recovery in PACU and throughout the first 24 hours postoperatively.
Ramsay Sedation Scale Score
Prazo: Upon recovery in PACU and during the first 2 hours postoperatively.

Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus).

Upon recovery in PACU and during the first 2 hours postoperatively.
Intraoperative Analgesic Consumption
Prazo: Intraoperatively measured from induction till end of surgery.

Total intraoperative fentanyl consumption.

Intraoperatively measured from induction till end of surgery.
Intraoperative Mean Arterial Pressure (MAP)
Prazo: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
Incidence of Side Effects and Complications
Prazo: Up to 24 hours postoperatively.

Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression.

It will be recorded as yes or No .

Up to 24 hours postoperatively.
Lactate Level
Prazo: Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.

Blood serum lactate level to assess metabolic stress.

Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
Postoperative Analgesic Consumption
Prazo: through 24 hours postoperatively.

Total postoperative meperidine consumption.

through 24 hours postoperatively.
Intraoperative Anesthetic Consumption
Prazo: Intraoperatively measured from induction till end of surgery.

Total intraoperative consumption of isoflurane and average end-tidal concentration

Intraoperatively measured from induction till end of surgery.
Intraoperative Heart Rate (HR)
Prazo: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

10 de janeiro de 2026

Conclusão Primária (Estimado)

1 de janeiro de 2027

Conclusão do estudo (Estimado)

1 de julho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

13 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de novembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • FMASU MD328/2025

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .